)
Edge3 Apr 2026
Extra Everything: The Story of Chipotle
Chipotle's story from a single restaurant to a nationwide chain, through crisis and turnaround, built on one of the strongest models in the industry.
Oruka Therapeutics
Oruka Therapeutics (ORKA) investor relations material
Oruka Therapeutics Registration filing summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Registration filing summary2 Apr, 2026
Company overview and business model
Clinical-stage biopharmaceutical company developing monoclonal antibody therapeutics for psoriasis and other inflammatory and immunology indications.
Focuses on antibody engineering and format innovations to improve efficacy and dosing regimens of standard-of-care medicines.
Lead programs target interleukin-23 (ORKA-001) and interleukin-17A/F (ORKA-002) for multiple chronic skin and inflammatory diseases.
Aims to set new treatment standards in large markets with unmet needs by leveraging proven mechanisms and half-life extension technology.
Financial performance and metrics
As of December 31, 2025, 48,722,309 shares of common stock and 137,138 shares of Series B Preferred Stock were outstanding.
Common stock last reported sale price was $50.43 per share on April 1, 2026.
Use of proceeds and capital allocation
Intended use of net proceeds from securities sales will be detailed in the applicable prospectus supplement; management retains broad discretion over allocation.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Oruka Therapeutics
- Advanced clinical pipeline and maintained strong liquidity, with key data readouts ahead.ORKA
Q4 202513 Mar 2026 - Annual and semi-annual biologics could redefine psoriatic disease treatment standards.ORKALeerink Global Healthcare Conference 202611 Mar 2026
- Ultra-long-acting antibodies target annual or biannual dosing and remission in psoriatic disease.ORKA44th Annual J.P. Morgan Healthcare Conference15 Jan 2026
- Advancing long-acting biologics for psoriasis with annual dosing and robust clinical catalysts ahead.ORKACorporate presentation12 Jan 2026
- Ultra-long-acting biologics aim to transform psoriatic disease care with multi-year remission.ORKATD Cowen 45th Annual Healthcare Conference22 Dec 2025
- Up to $500M in securities, including $200M ATM, to fund R&D after positive Phase 1 psoriasis data.ORKARegistration Filing16 Dec 2025
- Registering 39.4M shares for resale post-PIPEs, with lead antibody program advancing in Phase 2.ORKARegistration Filing16 Dec 2025
- Biopharma launches $200M at-the-market offering to fund antibody programs for psoriasis.ORKARegistration Filing16 Dec 2025
- Registering 39.4M shares for resale, with 59% of stock at risk of dilution and price pressure.ORKARegistration Filing16 Dec 2025
Next Oruka Therapeutics earnings date
Q1 202613 May, 2026
Oruka Therapeutics
Next Oruka Therapeutics earnings date
Q1 202613 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage